Rite Aid has decided to purchase pharmacy-benefit manager (PBM) Envision Pharmaceutical Services, also known as EnvisionRx, for roughly $2 billion, the Wall Street Journal reported Wednesday. The deal is expected to help Rite Aid compete with pharmacy retailers like CVS, which purchased the PBM Caremark Rx in 2006 for $21 billion. EnvisionRx has projected annual revenue of $5 billion, according to The New York Times. EnvisionRx’s chief executive Frank Sheeny is expected to run the PBM as a subsidiary of Rite Aid.
Please login or register first to view this content.